Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01201135
Other study ID # GDF-15CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 12, 2010
Last updated September 12, 2010
Start date September 2010
Est. completion date September 2011

Study information

Verified date September 2010
Source Wolfson Medical Center
Contact Ghoti Hossam, doctor
Phone 035028110
Email drghoti123@yahoo.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis


Description:

The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators.

In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

- non

Exclusion Criteria:

- non

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wolfson Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary GDF 15 year No
Secondary Hepcidine year No